(BPT) – Imagine waking up every day feeling utterly exhausted, no matter how much sleep you get. Now, add an unbearable itch that just won’t go away, dry eyes and mouth, and stomach pain. This is the ...
Please provide your email address to receive an email when new articles are posted on . More patients on elafibranor compared with placebo achieved biochemical response, with a 47% treatment benefit.
Content developed independently by our editors and supported by our partners. Carrington Garvin had been living the fun-packed life of a typical 21-year-old in Las Vegas—dating, working for a gaming ...
This indication was approved under accelerated approval based on a reduction of alkaline phosphatase. The Food and Drug Administration (FDA) has granted accelerated approval to Iqirvo ® (elafibranor) ...
BOSTON -- An investigational dual peroxisome proliferator-activated receptor (PPAR) agonist appeared effective as a second-line option for primary biliary cholangitis (PBC), according to phase III ...
OCALIVA received FDA accelerated approval in 2016 for the treatment of PBC in adults with an inadequate response to or intolerance of ursodeoxycholic acid (UDCA). Since then, OCALIVA has played a ...
Intercept Pharmaceuticals has voluntarily removed Ocaliva from the United States market for the treatment of primary biliary cholangitis, following a series of costly FDA rulings that have whittled ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback